title: Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood.
abstract: R6.5 (BIRR-1, Enlimomab), a murine IgG2a mAb to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. In initial clinical trials, R6.5 proved to be beneficial in reducing both disease activity in refractory rheumatoid arthritis and the incidence of acute rejection after kidney and liver allograft transplantations. However, adverse effects such as fever, leukopenia, or cutaneous reactions were not infrequent. We studied the effects of R6.5 on neutrophil function in whole blood samples ex vivo. Surprisingly, at the concentrations achieved in clinical trials, R6. 5 activated neutrophilic granulocytes, as indicated by a significant increase in expression of the adhesion molecule beta2-integrin CD11b, a concurrent decrease in L-selectin expression, and an enhancement of the oxidative burst activity. Neutrophil activation was not exerted by an anti-ICAM-1 mAb of the IgG1 isotype, by isotype-matched, irrelevant anti-2-phenyloxazolone mAb, or by F(ab')2 fragments of R6.5. Neutrophil activation was completely inhibited by soluble complement receptor type 1. We conclude that in whole blood, R6.5 activates resting neutrophils in a complement-dependent manner. This finding can explain, at least in part, the side effects associated with R6.5 therapy.
authors.affiliation: Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Vuorte
authors.forename: P J
authors.initials: PJ
authors.lastname: Lindsberg
authors.forename: M
authors.initials: M
authors.lastname: Kaste
authors.forename: S
authors.initials: S
authors.lastname: Meri
authors.forename: S E
authors.initials: SE
authors.lastname: Jansson
authors.forename: R
authors.initials: R
authors.lastname: Rothlein
authors.forename: H
authors.initials: H
authors.lastname: Repo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood* / Q000494:pharmacology*; D003170:Complement Pathway, Alternative / Q000276:immunology; D003171:Complement Pathway, Classical / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology*; D051379:Mice; D016853:Muromonab-CD3 / Q000097:blood / Q000494:pharmacology; D018375:Neutrophil Activation / Q000276:immunology*; D017463:Receptors, Complement 3b / Q000502:physiology